JP2022543402A - プロスタグランジンアナログを含む局所組成物 - Google Patents

プロスタグランジンアナログを含む局所組成物 Download PDF

Info

Publication number
JP2022543402A
JP2022543402A JP2022506712A JP2022506712A JP2022543402A JP 2022543402 A JP2022543402 A JP 2022543402A JP 2022506712 A JP2022506712 A JP 2022506712A JP 2022506712 A JP2022506712 A JP 2022506712A JP 2022543402 A JP2022543402 A JP 2022543402A
Authority
JP
Japan
Prior art keywords
composition
use according
latanoprost
hair
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543402A5 (enExample
Inventor
フランク レッシャー，
ベルンハルト ハウプトマイヤー，
Original Assignee
ノバリック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバリック ゲーエムベーハー filed Critical ノバリック ゲーエムベーハー
Publication of JP2022543402A publication Critical patent/JP2022543402A/ja
Publication of JP2022543402A5 publication Critical patent/JP2022543402A5/ja
Priority to JP2025129017A priority Critical patent/JP2025160428A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022506712A 2019-08-09 2020-08-06 プロスタグランジンアナログを含む局所組成物 Pending JP2022543402A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025129017A JP2025160428A (ja) 2019-08-09 2025-08-01 プロスタグランジンアナログを含む局所組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19191035.5 2019-08-09
EP19191035 2019-08-09
PCT/EP2020/072211 WO2021028328A1 (en) 2019-08-09 2020-08-06 Topical composition comprising a prostaglandin analogue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025129017A Division JP2025160428A (ja) 2019-08-09 2025-08-01 プロスタグランジンアナログを含む局所組成物

Publications (2)

Publication Number Publication Date
JP2022543402A true JP2022543402A (ja) 2022-10-12
JP2022543402A5 JP2022543402A5 (enExample) 2023-08-17

Family

ID=67587648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506712A Pending JP2022543402A (ja) 2019-08-09 2020-08-06 プロスタグランジンアナログを含む局所組成物
JP2025129017A Pending JP2025160428A (ja) 2019-08-09 2025-08-01 プロスタグランジンアナログを含む局所組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025129017A Pending JP2025160428A (ja) 2019-08-09 2025-08-01 プロスタグランジンアナログを含む局所組成物

Country Status (8)

Country Link
US (2) US20220362382A1 (enExample)
EP (1) EP4009952A1 (enExample)
JP (2) JP2022543402A (enExample)
KR (1) KR20220044739A (enExample)
CN (1) CN114206344A (enExample)
AU (2) AU2020330424A1 (enExample)
CA (1) CA3144193A1 (enExample)
WO (1) WO2021028328A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2714010T3 (en) 2011-05-25 2017-06-12 Novaliq Gmbh TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
EP4374851B1 (en) 2016-12-23 2026-04-15 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
SG11202007860XA (en) 2018-03-28 2020-09-29 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
WO2025133899A1 (en) 2023-12-19 2025-06-26 Glenmark Specialty S.A. Topical composition comprising dutasteride and latanoprost for alopecia
WO2025149998A1 (en) * 2024-01-11 2025-07-17 Glenmark Specialty S.A. Topical composition comprising clascoterone and latanoprost for alopecia
WO2026013128A1 (en) * 2024-07-10 2026-01-15 Dermaliq Therapeutics, Inc. Treatment of androgenetic alopecia

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511155A (ja) * 1997-02-04 2001-08-07 エイ． ジョンストン，マーレイ 毛髪の成長の増強方法
JP2005225817A (ja) * 2004-02-13 2005-08-25 Jiyugaoka Clinic 睫毛用育毛剤
JP2013510174A (ja) * 2009-11-09 2013-03-21 アラーガン インコーポレイテッド 発毛を刺激する組成物および方法
JP2013522272A (ja) * 2010-03-17 2013-06-13 ノバリック ゲーエムベーハー 眼圧上昇の治療のための医薬組成物
JP2017515855A (ja) * 2014-05-13 2017-06-15 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮治療システムにおける半フッ素化アルカン類の使用
WO2019063551A1 (en) * 2017-09-27 2019-04-04 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149484B2 (en) * 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
JP6023181B2 (ja) * 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
WO2013106565A1 (en) 2012-01-10 2013-07-18 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists
PT3442480T (pt) * 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511155A (ja) * 1997-02-04 2001-08-07 エイ． ジョンストン，マーレイ 毛髪の成長の増強方法
JP2005225817A (ja) * 2004-02-13 2005-08-25 Jiyugaoka Clinic 睫毛用育毛剤
JP2013510174A (ja) * 2009-11-09 2013-03-21 アラーガン インコーポレイテッド 発毛を刺激する組成物および方法
JP2013522272A (ja) * 2010-03-17 2013-06-13 ノバリック ゲーエムベーハー 眼圧上昇の治療のための医薬組成物
JP2017515855A (ja) * 2014-05-13 2017-06-15 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮治療システムにおける半フッ素化アルカン類の使用
WO2019063551A1 (en) * 2017-09-27 2019-04-04 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES

Also Published As

Publication number Publication date
AU2026202586A1 (en) 2026-04-23
US20260041773A1 (en) 2026-02-12
AU2020330424A1 (en) 2022-03-03
CA3144193A1 (en) 2021-02-18
JP2025160428A (ja) 2025-10-22
US20220362382A1 (en) 2022-11-17
CN114206344A (zh) 2022-03-18
EP4009952A1 (en) 2022-06-15
WO2021028328A1 (en) 2021-02-18
KR20220044739A (ko) 2022-04-11

Similar Documents

Publication Publication Date Title
US20260041773A1 (en) Topical composition comprising a prostaglandin analogue
RU2567792C2 (ru) Композиции и способы стимулирования роста волос
EP2640350B1 (en) Compositions and methods for hair growth
RU2703713C2 (ru) Композиции для местного нанесения, содержащие биматопрост, и способы стимуляции роста волос с их помощью
US9149484B2 (en) Compositions and methods for stimulating hair growth
EP4331683A2 (en) Methods and compositions for the treatment of hair loss
CA2784542C (fr) Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee
CA2539986C (en) Reduction of hair growth by applying an agonist of prostaglandin dp-receptor
TW200425890A (en) Method of stimulating hair growth using benzopyrans
US20040141935A1 (en) Reduction of hair growth
KR20260055529A (ko) 국소 조성물
CN114025768A (zh) 促进毛发生长的药品
JP2026513803A (ja) 脱毛の治療において使用するためのクラスコテロンとミノキシジルとの併用治療
UA118835C2 (uk) Композиція і спосіб стимулювання росту волосся
HK1188740B (en) Compositions and methods for hair growth
HK1188740A (en) Compositions and methods for hair growth

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250801